List of Excipients in Branded Drug ETONOGESTREL AND ETHINYL ESTRADIOL VAGINAL RING

Generic Drugs Containing ETONOGESTREL AND ETHINYL ESTRADIOL VAGINAL RING

Company	Ingredient	NDC	Excipient
Northstar Rx LLC	etonogestrel and ethinyl estradiol vaginal ring	16714-029	ETHYLENE-VINYL ACETATE COPOLYMER
Northstar Rx LLC	etonogestrel and ethinyl estradiol vaginal ring	16714-029	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in ETONOGESTREL AND ETHINYL ESTRADIOL VAGINAL RING?

# Of NDCs	Excipient
1	ETHYLENE-VINYL ACETATE COPOLYMER
1	MAGNESIUM STEARATE

Etonogestrel and Ethinyl Estradiol Vaginal Ring: Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Etonogestrel and ethinyl estradiol vaginal rings are mature combination contraceptive products with limited remaining opportunity in basic composition-of-matter claims. The principal commercial opportunities are in generic cost reduction, improved release consistency, packaging, storage, patient acceptability, manufacturing efficiency, and differentiated vaginal-ring platforms.

NuvaRing, originally developed by Organon, delivers etonogestrel and ethinyl estradiol continuously for three weeks, followed by a ring-free interval. The U.S. reference product contains 11.7 mg of etonogestrel and 2.7 mg of ethinyl estradiol and releases approximately 0.12 mg and 0.015 mg per day, respectively, over the labeled use period.[1]

What is the formulation of the etonogestrel and ethinyl estradiol vaginal ring?

The reference formulation is a drug-loaded ethylene-vinyl acetate, or EVA, ring with a rate-controlling outer membrane. The key formulation elements are:

Component	Role in the product
Etonogestrel	Progestin active ingredient
Ethinyl estradiol	Estrogen active ingredient
EVA copolymer with approximately 28% vinyl acetate	Drug-containing core and diffusion matrix
EVA copolymer with lower vinyl acetate content	Outer release-controlling membrane
Magnesium stearate	Processing aid and formulation excipient
Polymer ring geometry	Controls surface area, flexibility, drug loading and release

The ring has an outside diameter of approximately 54 mm and a cross-sectional diameter of approximately 4 mm.[1] The product is a reservoir or matrix-style polymeric delivery system rather than a conventional tablet or capsule.

The two active ingredients are dispersed in the polymeric core. The outer EVA membrane controls migration of the hormones from the core into the vaginal environment. Release depends on polymer composition, membrane thickness, active-ingredient loading, particle size, dispersion uniformity, ring dimensions and storage history.

Why is EVA the dominant excipient platform?

EVA is commercially attractive because it combines flexibility, chemical resistance, processability and controlled diffusion of steroid hormones. Its vinyl acetate content can be adjusted to change polymer polarity, mechanical properties and permeability.

Higher vinyl acetate content generally increases polymer flexibility and can affect hormone diffusion. A lower-vinyl-acetate outer membrane can provide a tighter release barrier than the drug-containing core. This creates a practical formulation architecture in which the core supplies drug and the membrane controls delivery.

EVA also supports continuous manufacturing processes, including hot-melt extrusion, co-extrusion, molding and precision cutting or joining of ring segments. These processes are better suited to high-volume production than labor-intensive systems based on silicone elastomers or manually assembled multilayer devices.

The principal technical risks are hormone crystallization, drug migration during storage, nonuniform distribution, changes in release rate after sterilization or heat exposure, polymer oxidation, residual solvent, and variation in ring dimensions.

What excipients are most relevant to a generic vaginal ring?

The main excipient strategy is to remain close to the reference formulation while improving process control. A materially different excipient system can increase the burden of comparative dissolution, drug-release, stability and local-tolerance studies.

EVA copolymer selection

A generic manufacturer can evaluate:

• EVA grade and vinyl acetate percentage
• Molecular weight and melt-flow index
• Polymer supplier and residual monomer profile
• Core-to-membrane composition
• Membrane thickness
• Polymer crystallinity and processing temperature
• Use of a single polymer grade versus a multilayer design

Changing the EVA grade may affect both release kinetics and mechanical behavior. The commercial advantage of a new grade is limited unless it reduces manufacturing cost, improves dose uniformity or creates a differentiated release profile.

Magnesium stearate

Magnesium stearate is used in the reference formulation as a processing excipient. It can improve handling and reduce adhesion during manufacture, but its concentration and particle-size distribution can influence drug dispersion and extrusion behavior.

A manufacturer seeking a formulation patent could investigate alternative lubricants or processing aids. Such substitutions would need to preserve hormone stability, ring integrity, extractables and leachables performance, and release behavior.

Antioxidants and stabilizers

Steroid products may be exposed to thermal and oxidative stress during compounding, extrusion, packaging and storage. Antioxidants or stabilizers could improve shelf life, but they introduce regulatory and toxicological questions for a product intended for prolonged mucosal contact.

Any stabilizer must be evaluated for:

• Vaginal irritation and sensitization
• Migration from the polymer
• Extractables and leachables
• Hormone compatibility
• Residual levels at the end of shelf life
• Impact on drug release

The strongest commercial case is a low-level stabilizer that reduces degradation without changing the established release profile.

What formulation patents could protect an etonogestrel and ethinyl estradiol ring?

Protection can arise from several claim categories even when the active ingredients are no longer strongly protected.

Polymer composition claims

These claims can cover a specified EVA grade, vinyl acetate range, molecular-weight range, polymer ratio or additive concentration. Their commercial value depends on whether competing manufacturers can design around the claimed ranges without sacrificing performance.

Ring architecture claims

Claims may cover:

• Core-shell structures
• Drug-loaded core and inert membrane
• Co-extruded layers
• Specific membrane thickness
• Defined ring dimensions
• Separate drug reservoirs
• Placement of the two hormones in different layers

Architecture claims can be more durable than simple ingredient claims because they target the delivery device rather than the active substances.

Release-profile claims

A formulation patent may define daily release rates, total dose released over 21 days, or release uniformity within a specified range. These claims can be difficult to enforce unless the product’s release profile is readily measurable and falls within the claimed boundaries.

Manufacturing-method claims

Potential claims may cover hot-melt extrusion temperature, mixing sequence, active-ingredient particle size, cooling conditions, joining technique, in-line dimensional inspection or packaging under controlled humidity.

Manufacturing claims are commercially relevant when they reduce scrap, improve content uniformity or solve a stability problem. They are harder to detect in an accused competitor’s product because the process may occur inside a confidential manufacturing facility.

What is the FDA status of etonogestrel and ethinyl estradiol vaginal rings?

NuvaRing was approved under U.S. NDA 021187. The FDA-approved product is a monthly vaginal contraceptive ring that is inserted for three weeks and removed for one week.[1]

The first widely marketed U.S. generic, EluRyng, was approved by the FDA in 2019. EluRyng is an abbreviated new drug application product referencing NuvaRing and uses the same active ingredients and general delivery concept.[2] Other products may be approved in different markets under separate brand or generic names.

Annovera is not an etonogestrel and ethinyl estradiol ring. It contains segesterone acetate and ethinyl estradiol and uses a reusable system with a different active ingredient, product design and regulatory profile.[3] It is a competitive vaginal-ring product but not a direct generic substitute for NuvaRing.

When did the key exclusivity and patent barriers expire?

The principal U.S. exclusivity barriers for the etonogestrel and ethinyl estradiol ring have expired. NuvaRing was approved in 2001, and its core commercial protection has historically been associated with patents covering the hormone-containing vaginal ring and controlled release from the polymeric device.[1,4]

The relevant competitive situation is now defined less by basic patent exclusivity and more by:

• FDA approval requirements
• Bioequivalence or pharmaceutical-equivalence expectations
• Manufacturing know-how
• Device performance
• Supply reliability
• Brand recognition
• Payer contracting
• State and international regulatory requirements

The FDA Orange Book should be checked for the current patent and exclusivity entries associated with NDA 021187 because listed patents and regulatory certifications can change over time.[4] A generic applicant may use an ANDA pathway and make a Paragraph IV certification against any unexpired listed patent, but the commercial relevance of a Paragraph IV challenge depends on whether a listed patent remains enforceable and whether litigation triggers a 30-month stay under the Hatch-Waxman framework.[5]

Are Paragraph IV challenges still a major risk for this product?

For the mature etonogestrel and ethinyl estradiol ring, Paragraph IV risk is generally lower than for a recently approved drug. The principal exposure is not the original reference product’s expired core technology. It is the potential assertion of later patents covering a specific generic formulation, process, packaging system or improved delivery profile.

A later entrant should assess:

1. Current Orange Book listings for NuvaRing and approved reference products.
2. Patent term, pediatric extensions and terminal disclaimers.
3. ANDA certification strategy.
4. Whether the proposed formulation falls within any active device or manufacturing claim.
5. Abbreviated new drug application suitability.
6. Potential litigation over formulation similarity or product-by-process limitations.

An ANDA applicant also faces nonpatent barriers. The applicant must demonstrate acceptable pharmaceutical equivalence, drug release, stability and quality. A ring that delivers the correct total dose but produces a different early-release profile may create regulatory and commercial problems.

What excipient strategies create the strongest commercial opportunities?

Low-cost generic EVA platform

The most immediate opportunity is a conventional EVA formulation that closely matches the reference product. Value comes from procurement, cycle-time reduction, automated assembly and lower rejection rates rather than from a new excipient.

The highest-impact manufacturing variables are polymer yield, hormone recovery, ring dimensional tolerance, content uniformity and packaging throughput.

Long-acting or extended-use ring

A ring designed for use beyond the standard three-week period could create a new product category. It would require controlled reduction of daily hormone release, sufficient residual drug at the end of the intended use period, and clinical evidence for contraceptive efficacy and tolerability.

This strategy has a stronger patent position because it can combine:

• Extended-duration use
• New release kinetics
• Specific polymer architecture
• Defined residual drug content
• Packaging and replacement schedules

It would likely require more than a conventional ANDA strategy.

Lower-dose estrogen ring

A lower-dose ethinyl estradiol formulation could target users seeking reduced estrogen exposure. The commercial opportunity depends on maintaining contraceptive efficacy, cycle control and tolerability. Such a product could be protected through dose, release-profile and method-of-use claims, although clinical development requirements would increase.

Hormone-segregated ring

Placing etonogestrel and ethinyl estradiol in separate polymer regions could improve control over independent release rates. The architecture may help reduce drug-drug interaction within the polymer and could support differentiated dosing.

The tradeoff is greater manufacturing complexity and a more demanding analytical program.

Improved comfort and insertion

A softer ring, smoother surface, lower force during compression, or improved dimensional consistency could support a premium generic or over-the-counter-oriented strategy. These improvements are more likely to support device, design or user-experience claims than conventional pharmaceutical composition claims.

Packaging and stability

Packaging is an underdeveloped commercial opportunity. A barrier pouch with improved moisture, oxygen and light protection could extend shelf life or support distribution in hot and humid markets. A compact applicator, tamper-evident package or calendar-based storage system could improve adherence.

Packaging changes must account for hormone sorption, polymer interaction, extractables and leachables, and transport conditions.

How strong is the patent estate for an etonogestrel and ethinyl estradiol ring?

The estate is strongest for new delivery systems and weakest for the basic combination itself.

Technology area	Patent strength for a new entrant	Commercial assessment
Etonogestrel plus ethinyl estradiol combination	Low	Mature active ingredients
Conventional EVA ring	Low to moderate	Design-around options exist
Specific multilayer architecture	Moderate	Can support differentiated claims
Extended-duration release	Moderate to strong	Requires clinical and regulatory support
Manufacturing process	Moderate	Valuable but harder to detect and enforce
Packaging and stability system	Moderate	Useful for lifecycle management
Applicator or comfort design	Moderate	Device-focused differentiation
Method of use	Moderate	Depends on new dosing schedule or patient population

Patent value depends on claim scope, remaining term, enforceability and freedom-to-operate analysis. A broad claim directed to a vaginal ring containing the two hormones may face validity and expiration constraints. A narrow claim directed to polymer ratios, dimensions or release windows may survive but may be easier to design around.

Which companies compete in the vaginal contraceptive ring market?

The commercial landscape includes:

• Organon, associated with NuvaRing and the reference product
• Amneal Pharmaceuticals, associated with EluRyng
• Therapeutic-device developers pursuing reusable or extended-use rings
• Regional generic manufacturers supplying markets outside the United States

The most direct competition is between NuvaRing and generic etonogestrel/ethinyl estradiol rings. Annovera competes for the same vaginal contraceptive-use case but has a different active ingredient, product life and use schedule.[2,3]

The commercial ceiling for a conventional generic is constrained by price competition and limited differentiation. Better opportunities exist in differentiated rings with longer use, improved tolerability, lower estrogen exposure or simplified packaging.

What revenue exposure and launch risks matter for investors?

Revenue exposure is concentrated in a small number of factors:

• Share retained by the reference brand
• Generic approval timing
• Number of approved generic competitors
• Payer substitution rules
• Manufacturing capacity
• Product recalls or supply interruptions
• Patient willingness to use a vaginal delivery system
• Competitive pressure from oral contraceptives, long-acting reversible contraceptives and other rings

A conventional generic launch can be rapid after approval but may face immediate price erosion. A branded lifecycle product can preserve pricing only if it offers a clinically meaningful benefit, such as extended use or reduced hormone exposure.

The largest operational risks are polymer supply, active-ingredient dispersion, ring breakage, release-rate drift and pouch integrity. These risks can affect both regulatory approval and commercial continuity.

What generic launch scenarios exist?

Conventional ANDA launch

This is the lowest-risk development path. The applicant uses an EVA ring with the same active ingredients and a closely comparable release profile. The main advantages are lower development cost and a clear regulatory reference point.

Formulation-differentiated launch

The applicant changes the polymer, membrane or packaging while preserving the same active ingredients. This may create patent value but increases analytical, stability and regulatory risk.

Extended-use launch

The applicant develops a ring for a longer period than the standard regimen. This offers the strongest commercial differentiation but probably requires clinical evidence and a full or hybrid regulatory strategy rather than a simple generic pathway.

International launch

Countries outside the United States may provide opportunities where generic competition is less intense or where local manufacturing incentives apply. Patent status, device classification and bioequivalence requirements must be assessed country by country.

Key Takeaways

• The reference product uses an EVA polymer ring with etonogestrel, ethinyl estradiol and magnesium stearate.[1]
• Basic combination and conventional-ring protection is mature, reducing the value of composition-of-matter patent strategies.
• Generic opportunity is strongest in process efficiency, supply reliability, packaging and close formulation matching.
• The most valuable new patent positions are likely to involve extended use, multilayer architecture, controlled release, lower estrogen exposure or improved device performance.
• EluRyng is a direct U.S. generic competitor to NuvaRing.[2]
• Annovera competes in the vaginal-ring category but contains segesterone acetate rather than etonogestrel.[3]
• Current Orange Book listings and patent certifications should be reviewed before an ANDA filing or launch decision.[4,5]
• Manufacturing know-how may be more commercially important than broad formulation patents for a conventional generic.

FAQs

Can a new manufacturer use a different polymer from EVA?

Yes, but a different polymer would require evidence that the ring has acceptable drug release, stability, mechanical integrity, biocompatibility and manufacturing consistency. A different polymer may support product differentiation but increases regulatory risk.

Is magnesium stearate essential to the vaginal ring?

No. It is an excipient used in the reference formulation, but an alternative processing aid may be possible if the substitute preserves content uniformity, release performance, stability and mucosal safety.

Can an etonogestrel and ethinyl estradiol ring be marketed as an over-the-counter product?

Potentially, but the regulatory pathway would depend on FDA requirements for nonprescription use, labeling comprehension, self-selection and safe use. A switch from prescription to nonprescription status would require a separate regulatory strategy.

What is the main formulation failure mode for a generic ring?

Release-rate variability is a major risk. It can arise from nonuniform hormone dispersion, changes in EVA grade, membrane thickness variation, polymer processing temperature or active-ingredient crystallization.

Can packaging improvements support a separate patent?

Yes. A packaging patent may cover barrier materials, pouch structure, humidity control, light protection, device storage or a package-and-ring combination. Commercial value depends on whether the packaging improves shelf life, transport stability or patient adherence.

References

1. U.S. Food and Drug Administration. (2024). NuvaRing prescribing information, NDA 021187. FDA.

2. U.S. Food and Drug Administration. (2019). FDA approves first generic version of NuvaRing. FDA.

3. U.S. Food and Drug Administration. (2020). Annovera prescribing information, NDA 209627. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).